Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : NIH begins clinical trial testing COVID-19 vaccine in pregnant women

06/23/2021 | 03:12pm EDT

June 23 (Reuters) - The U.S. National Institutes of Health (NIH) said on Wednesday it had begun a study to evaluate the immune responses generated by COVID-19 vaccines in pregnant or postpartum women.

Pregnant women are at higher risk of complications including premature birth, high blood pressure with organ failure risk, need for intensive care and possible death, according to the NIH.

A research study conducted in February in Israel showed that antibodies were detected in all 20 women administered with both the doses of the Pfizer/BioNTech vaccine during their third trimester of pregnancy and also in their newborns.

Pfizer and BioNTech in February started a separate trial, with 4,000 international volunteers, evaluating safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.

The NIH study, MOMI-VAX, will measure the development and durability of antibodies against the coronavirus in women vaccinated during pregnancy or the first two postpartum months.

The researchers will assess vaccine safety and also evaluate whether vaccinated pregnant women pass along protection to their babies via the placenta or breast milk.

Many pregnant women in the United States have already received the COVID-19 vaccine available under emergency use authorization.

"The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy," National Institute of Allergy and Infectious Diseases Director (NIAID) Dr Anthony Fauci said. NIAID is financing the study.

The trial will enroll up to 750 pregnant and 250 postpartum women within two months of delivery, who have already received or will receive a COVID-19 vaccine authorized by the U.S. Food and Drug Administration (FDA).

The FDA has authorized vaccines from Moderna, Pfizer-BioNTech and Johnson & Johnson for emergency use. (Reporting by Dania Nadeem in Bengaluru)


© Reuters 2021
All news about MODERNA, INC.
07/31MODERNA : U.S. administers 345.6 mln doses of COVID-19 vaccines - CDC
RE
07/31MODERNA : U.S. CDC Says Delivered 400,675,525 Doses Of COVID-19 Vaccine As Of Ju..
RE
07/30MODERNA : U.S. administers 344.93 mln doses of COVID-19 vaccines - CDC
RE
07/30MODERNA : Most COVID-19 cases in Massachusetts outbreak among vaccinated, says C..
RE
07/30MODERNA : U.S. CDC Says Delivered 399,090,105 Doses Of Covid-19 Vaccine As Of Ju..
RE
07/30CORONAVIRUS - BOTSWANA : No vaccine manufacturing company has withdrawn from an ..
AQ
07/30Misleading With Numbers
AQ
07/30States race to use COVID-19 vaccines before they expire
AQ
07/29MODERNA : Conservatives push feds to ensure Canadians who got mixed vaccines can..
AQ
07/29MODERNA : U.S. administers 344.1 mln doses of COVID-19 vaccines - CDC
RE
More news
Financials (USD)
Sales 2021 19 103 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 14,0x
Yield 2021 -
Capitalization 142 B 142 B -
EV / Sales 2021 6,81x
EV / Sales 2022 7,64x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 353,60 $
Average target price 187,73 $
Spread / Average Target -46,9%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837
PHARMARON BEIJING CO., LTD.64.43%23 159